Brazil is home to the world's largest mosquito biofactory, a facility designed to combat catastrophic surges in mosquito-borne illnesses like dengue, Zika, and chikungunya. [1, 2]

The primary facility, known as Wolbito do Brasil, is located in Curitiba, Brazil, and marks a massive shift toward using biotechnology as a national public health strategy. [1, 2]

The Core Technology: The Wolbachia Method

The factory breeds Aedes aegypti mosquitoes that are intentionally infected with a naturally occurring bacterium called Wolbachia. [1, 2]

• Virus Blocker: Wolbachia is completely harmless to humans but blocks viruses like dengue from multiplying inside the mosquito's body. [1, 2]

• Self-Sustaining Population: When these "good mosquitoes" (locally called wolbitos) are released into the wild, they mate with local populations. [1, 2]

• Genetic Handover: Female mosquitoes pass the bacterium down to their offspring, gradually replacing the disease-carrying wild population over time. [1, 2]

Factory Operations & Scale

The massive scale of production is a direct response to Brazil's historic public health challenges, which peaked with over 6.5 million dengue cases in a single outbreak. [1]

• Massive Output: The Curitiba biofactory covers over 3,500 square meters and is built to produce 100 million mosquito eggs per week (over 5 billion per year). [1, 2]

• Partnership Driven: The facility operates as a joint venture between the non-profit https://www.worldmosquitoprogram.org/news-stories/brazil-opens-worlds-largest-mosquito-biofactory&ved=2ahUKEwiR66TPraCWAxU7RzABHb3WNKgQy_kOegoIAggACAAIGxAJ&opi=89978449&cd&psig=AOvVaw10jC5qy8PKXcZ4yB9c9qBL&ust=1786805041010000" data-copy-service-computed-style="font-family: Google Sans, Arial, sans-serif; font-size: 16px; font-weight: 500; margin: 0px; text-decoration: underline 1px rgb(26, 13, 171); border-bottom: 0px rgb(26, 13, 171);">World Mosquito Program (WMP), the Oswaldo Cruz Foundation (Fiocruz), and the Institute of Molecular Biology of Paraná (IBMP). [1, 2]

• Long-term Goal: The project aims to protect more than 140 million Brazilians across the country over the next decade. [1, 2]

• Proven Success: In early pilot cities like Niterói, areas fully populated by wolbitos saw an incredible 89% reduction in dengue cases. [1]

Alternative Commercial Facilities

In addition to the public-private Wolbito facility, international biotech companies operate in the region. For example, the British company Oxitec has a massive production footprint in Campinas, São Paulo, capable of outputting up to 190 million mosquitoes weekly using similar bio-friendly targeting methods to dramatically drive down local disease transmission.